Tolerability and Pharmacokinetics/-Dynamics of 0.5 mg and 1.0 mg (Actual 0.8 mg) of BIBT 986 BS Per Hour Given as IV Infusion Over 32 Hours in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Vss (Apparent volume of distribution at steady state following intravascular administration)
研究概览
简要总结
Study to assess the tolerability of an intravenous infusion of 0.5 and 1.0 mg (actual 0.8 mg) BIBT 986 BS per hour over 32 hours as well as pharmacokinetics and the effect on blood coagulation parameters
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects as determined by results of screening
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Age >= 18 and <= 55 years
- •BMI >= 18.5 and <= 29.9 kg/m2
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •Relevant history of orthostatic hypotension, fainting spells or blackouts
- •Abnormal PT, TT, aPTT (must be within the normal range after no more than one repeated test), thrombocytes < 150000/μl (two repeats of the first test)
- •Evidence of hematuria either macroscopically detectable or microscopic on urinalysis (normal microscopic results after no more than one repeated test)
- •Evidence of blood dyscrasia, hemorrhagic diathesis, severe thrombocytopenia, cerebrovascular hemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with hemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, Central nervous system (CNS) trauma, retinopathy, nephrolithiasis)
- •Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of CNS or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
- •Occult blood in 1 of 3 subsequent faecal samples collected for the pre-study examination
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- •Use of any drugs, within 14 days prior to administration or during the trial
- •Participation in another trial with an investigational drug (< 2 months prior to administration or during trial)
- •Smoker (> 10 cigarettes or >3 cigars or >3 pipes/day)
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood donation or loss > 400 mL, < 1 month prior to administration or during the trial
- •Excessive physical activities < 5 days prior to administration of study drug or during trial
- •Clinically relevant laboratory abnormalities
- •Veins unsuited for i.v. puncture and administration of prolonged infusions on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
研究组 & 干预措施
BIBT 986 BS - low
干预措施: BIBT 986 BS - low (Drug)
BIBT 986 BS - high
干预措施: BIBT 986 BS - high (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Vss (Apparent volume of distribution at steady state following intravascular administration)
时间窗: up to 48 hours post dose
Amount of parent drug eliminated in urine (Ae)
时间窗: up to 48 hours post dose
CT (concentration of the analyte at the end of drug infusion)
时间窗: up to 48 hours post dose
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 48 hours post dose
Tmax (time from dosing to the maximum concentration of the analyte in plasma)
时间窗: up to 48 hours post dose
AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration)
时间窗: up to 48 hours post dose
AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after single dose administration)
时间窗: up to 48 hours post dose
λz (terminal rate constant of the analyte in plasma)
时间窗: up to 48 hours post dose
Css (steady state concentration of the analyte in plasma following a constant rate infusion)
时间窗: up to 48 hours post dose
t1/2 (Terminal half-life of the analyte in plasma after single dose administration)
时间窗: up to 48 hours post dose
CLR (renal clearance of the analyte in plasma following intravascular administration)
时间窗: up to 48 hours post dose
MRTinf (mean residence time of the analyte in the body after intravenous infusion)
时间窗: up to 48 hours post dose
Change in prothrombin time (PT)
时间窗: up to 48 hours post dose
Number of subjects with adverse events
时间窗: up to 4 days
Number of subjects with clinically significant changes in vital signs
时间窗: up to 4 days
Pulse rate, systolic \& diastolic blood pressure
Fraction of administered drug excreted unchanged in urine (fe)
时间窗: up to 48 hours post dose
CL (Total clearance of the analyte in plasma following intravascular administration)
时间窗: up to 48 hours post dose
Vz (apparent volume of distribution during the terminal phase λz following intravascular administration)
时间窗: up to 48 hours post dose
Change in activated partial thromboplastin time (aPTT)
时间窗: up to 48 hours post dose
Change in thrombin time (TT)
时间窗: up to 48 hours post dose
Change in International Normalised Ratio (INR)
时间窗: up to 48 hours post dose
Change in ecarin clotting time (ECT)
时间窗: up to 48 hours post dose
次要结局
未报告次要终点